Ergomed PLC
LSE:ERGO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Ergomed PLC
Accounts Receivables
Ergomed PLC
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ergomed PLC
LSE:ERGO
|
Accounts Receivables
£31.3m
|
CAGR 3-Years
17%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Accounts Receivables
£72.4m
|
CAGR 3-Years
20%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Accounts Receivables
£14.8m
|
CAGR 3-Years
28%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
G
|
Genedrive PLC
LSE:GDR
|
Accounts Receivables
£346k
|
CAGR 3-Years
40%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-18%
|
|
|
Fusion Antibodies PLC
LSE:FAB
|
Accounts Receivables
£868k
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
Accounts Receivables
£13.9m
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
13%
|
|
Ergomed PLC
Glance View
Ergomed Plc is a clinical stage development company, which provides specialist services to the pharmaceutical and biotechnology industries spanning all phases of clinical development, post-approval pharmacovigilance, and medical information. The company is headquartered in Guildford, Surrey. The company went IPO on 2014-07-15. The firm operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The firm operates approximately 24 offices around the world, providing its services in over 100 countries globally. The company operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Company’s subsidiaries include Ergomed GmbH, Ergomed Sp. z o.o, Ergomed d.o.o. Beograd, Ergomed Clinical Research Inc., MS Clinical Services, LLC and MedSource UK Ltd.
See Also
What is Ergomed PLC's Accounts Receivables?
Accounts Receivables
31.3m
GBP
Based on the financial report for Jun 30, 2023, Ergomed PLC's Accounts Receivables amounts to 31.3m GBP.
What is Ergomed PLC's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
22%
Over the last year, the Accounts Receivables growth was -9%. The average annual Accounts Receivables growth rates for Ergomed PLC have been 17% over the past three years , 22% over the past five years .
